NCT07486713 2026-03-20Olutasidenib DDI Study in Patients With IDH1 Mutation Positive MalignanciesRigel PharmaceuticalsPhase 4 Recruiting16 enrolled
NCT02386800 2026-03-16CINC424A2X01B Rollover ProtocolNovartisPhase 4 Active not recruiting279 enrolled